Exelixis, Inc. (NASDAQ:EXEL) is recovering after its plunge yesterday by close to 40% post the company’s statement that it wants to take its clinical trial forward. The study trial relates to testing its drug cabozantinib aimed at treating patients with prostate cancer. Although the continuation of the trial does not appear to be such a bad news to push the stock down, but there are multiple concerns that the investors are jittery about. Firstly, the investors had anticipated the trial to end before the scheduled date. As per analyst, the continuation of trial points out to downbeat result of the drug, as compared to other drugs, which completed late-stage trials before schedule. Exelixis, Inc. (NASDAQ:EXEL) shares after opening at $3.90 moved to $3.91 on last trade day and at the end of the day closed at $3.38. Company price to sales ratio in past twelve months was calculated as 21.02 and price to cash ratio as 2.58. Exelixis, Inc. (NASDAQ:EXEL) showed a negative weekly performance of -46.26%.
Sangamo Biosciences (NASDAQ:SGMO) CMO Dale G. Ando unloaded 15,000 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $18.65, for a total value of $279,750.00. Following the completion of the sale, the chief marketing officer now directly owns 97,015 shares in the company, valued at approximately $1,809,330. The sale was disclosed in a filing with the SEC, which is available at this link. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares fell -5.37% in last trading session and ended the day on $16.74. SGMO return on equity ratio is recorded as -28.90% and its return on assets is -24.70%. Sangamo Biosciences, Inc. (NASDAQ:SGMO) yearly performance is 75.10%.
March 20, Mar 20, 2014 Receptos Inc (NASDAQ:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced that its President and Chief Executive Officer, Faheem Hasnain, will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 10:00 am Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company’s website at www.receptos.com . A replay will be available for 14 days after the event.Receptos Inc (NASDAQ:RCPT) shares moved down -1.34% in last trading session and was closed at $39.63, while trading in range of $39.14-$41.33. Receptos Inc (NASDAQ:RCPT) year to date performance is 36.70%.
The Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Mar. 3 reported business and financial highlights for the fourth quarter and year ended December 31, 2013 and outlined the Company’s major clinical development goals for 2014. Total revenue was $0.6 million in the fourth quarter of 2013 and $4.1 million for the twelve months ended December 31, 2013, compared to $3.6 million and $11.2 million for the comparable periods in 2012. Net loss was $22.1 million, or ($0.27) per share, for the fourth quarter of 2013 and $81.6 million, or ($1.02) per share, for the twelve months ended December 31, 2013, compared to net loss of $16.8 million, or ($0.27) per share, and $59.1 million, or ($1.02) per share, for the comparable periods in 2012. Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is -21.24%. On last trading day company shares ended up $16.95. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average is -35.04%. Analysts mean target price for the company is $36.33.
Leave a Reply